What does AT220 — financial royalty assets, allowance mean?

This metric reflects the cumulative valuation adjustments, such as expected credit losses or impairment reserves, applied to the royalty assets of the AT220 segment. It acts as a contra-asset account that accounts for potential risks or declines in the projected future cash flows from these specific royalty streams. A significant increase in this allowance may signal management's concern regarding the commercial viability or collectability of the underlying pharmaceutical partnerships.

Ligand Pharmaceuticals LGND AT220 — Financial Royalty Assets, Allowance

Other product segments

Qarziba

$480K—

Similar metrics at other companies

NOVRoyalty — Contract With Customer Receivable Allowance For Credit Loss

$78M+144%

NOVRoyalty — Contract With Customer Receivable After Allowance For Credit Loss

$43M+231%

IONSTax Credit Carryforward Valuation Allowance

$1.24B+9.5%

OGS

OGSAllowance for Doubtful Accounts

$14.6M-12.6%

APOAsset Management — Total Valuation Allowance

$54M+100%

JAN

JANTax Credit Carryforward Valuation Allowance

$8.96M+207%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's at220 — financial royalty assets, allowance.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's AT220 — financial royalty assets, allowance?: Ligand Pharmaceuticals (LGND) reported AT220 — financial royalty assets, allowance of $121K in Q1 2026.
What does AT220 — financial royalty assets, allowance mean?: This metric reflects the cumulative valuation adjustments, such as expected credit losses or impairment reserves, applied to the royalty assets of the AT220 segment. It acts as a contra-asset account that accounts for potential risks or declines in the projected future cash flows from these specific royalty streams. A significant increase in this allowance may signal management's concern regarding the commercial viability or collectability of the underlying pharmaceutical partnerships.